|
Name |
Cyclonerodiol
|
Molecular Formula | C15H28O2 | |
IUPAC Name* |
(1R,2S,3R)-3-[(2R)-2-hydroxy-6-methylhept-5-en-2-yl]-1,2-dimethylcyclopentan-1-ol
|
|
SMILES |
C[C@H]1[C@@H](CC[C@@]1(C)O)[C@@](C)(CCC=C(C)C)O
|
|
InChI |
InChI=1S/C15H28O2/c1-11(2)7-6-9-15(5,17)13-8-10-14(4,16)12(13)3/h7,12-13,16-17H,6,8-10H2,1-5H3/t12-,13+,14+,15+/m0/s1
|
|
InChIKey |
ZBJPVPFEDGYYBD-GBJTYRQASA-N
|
|
Synonyms |
Cyclonerodiol; 28834-06-2; 4ZP8FLH4RC; UNII-4ZP8FLH4RC; DTXSID80183022; (1R,2S,3R)-3-[(2R)-2-hydroxy-6-methylhept-5-en-2-yl]-1,2-dimethylcyclopentan-1-ol; Cyclopentanemethanol, 3-hydroxy-alpha,2,3-trimethyl-alpha-(4-methyl-3-penten-1-yl)-, (alphaR,1R,2S,3R)-; Cyclopentanemethanol, 3-hydroxy-alpha,2,3-trimethyl-alpha-(4-methyl-3-pentenyl)-, (1R-(1alpha(R*),2beta,3beta))-
|
|
CAS | 28834-06-2 | |
PubChem CID | 168840 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 240.38 | ALogp: | 3.2 |
HBD: | 2 | HBA: | 2 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 40.5 | Aromatic Rings: | 1 |
Heavy Atoms: | 17 | QED Weighted: | 0.728 |
Caco-2 Permeability: | -4.307 | MDCK Permeability: | 0.00001970 |
Pgp-inhibitor: | 0.551 | Pgp-substrate: | 0.004 |
Human Intestinal Absorption (HIA): | 0.015 | 20% Bioavailability (F20%): | 0.895 |
30% Bioavailability (F30%): | 0.021 |
Blood-Brain-Barrier Penetration (BBB): | 0.214 | Plasma Protein Binding (PPB): | 91.63% |
Volume Distribution (VD): | 1.35 | Fu: | 6.58% |
CYP1A2-inhibitor: | 0.126 | CYP1A2-substrate: | 0.389 |
CYP2C19-inhibitor: | 0.126 | CYP2C19-substrate: | 0.883 |
CYP2C9-inhibitor: | 0.078 | CYP2C9-substrate: | 0.776 |
CYP2D6-inhibitor: | 0.029 | CYP2D6-substrate: | 0.112 |
CYP3A4-inhibitor: | 0.066 | CYP3A4-substrate: | 0.233 |
Clearance (CL): | 8.19 | Half-life (T1/2): | 0.345 |
hERG Blockers: | 0.025 | Human Hepatotoxicity (H-HT): | 0.257 |
Drug-inuced Liver Injury (DILI): | 0.079 | AMES Toxicity: | 0.003 |
Rat Oral Acute Toxicity: | 0.011 | Maximum Recommended Daily Dose: | 0.011 |
Skin Sensitization: | 0.469 | Carcinogencity: | 0.101 |
Eye Corrosion: | 0.898 | Eye Irritation: | 0.965 |
Respiratory Toxicity: | 0.022 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002414 | 0.750 | D0W6DG | 0.275 | ||||
ENC004079 | 0.579 | D0M1PQ | 0.273 | ||||
ENC004078 | 0.559 | D07QKN | 0.267 | ||||
ENC003948 | 0.559 | D0X7XG | 0.233 | ||||
ENC004067 | 0.525 | D03VFL | 0.220 | ||||
ENC001455 | 0.450 | D02VPX | 0.204 | ||||
ENC005926 | 0.429 | D0S7WX | 0.202 | ||||
ENC003627 | 0.368 | D05BTM | 0.200 | ||||
ENC002152 | 0.367 | D0T2PL | 0.200 | ||||
ENC002289 | 0.358 | D05XQE | 0.195 |